Effect of Probiotics on Mycoplasma Pneumoniae Pneumonia
Not Applicable
Not yet recruiting
- Conditions
- Mycoplasma Pneumoniae Pneumonia
- Interventions
- Dietary Supplement: PlaceboDietary Supplement: Probiotic
- Registration Number
- NCT06348095
- Lead Sponsor
- Wecare Probiotics Co., Ltd.
- Brief Summary
To evaluate the effectiveness and safety of compound probiotic in shortening the course of illness in children with mycoplasma pneumoniae pneumonia, in comparison with placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
- Meet the diagnostic criteria for pneumonia in "Zhufutang Practical Pediatrics" (7th Edition), and is diagnosed with Mycoplasma pneumoniae pneumonia using tNGS technology;
- Infants and young children aged 6 months to 3 years;
- The course of the disease is <48 h;
- The family members of the children are informed about the study and sign the informed consent form.
Read More
Exclusion Criteria
- Previous history of wheezing;
- Cardiovascular disease and congenital tracheal dysplasia;
- pneumonia induced by other causes;
- Dysplasia of bronchial and pulmonary tracts;
- premature infants;
- Combined with immunosuppressive diseases;
- Presence of mental illness.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo group Placebo Maltodextrin, one strip/ day WecProB, before meals; Storage: Store in a cool, dry place without sun exposure. Probiotics group Probiotic 2B CFU/ strip/ day WecProB, before meals; Storage: Store in a cool, dry place without sun exposure.
- Primary Outcome Measures
Name Time Method Mycoplasma pneumoniae load 7天 Mycoplasma pneumoniae load was detected by tNGS
- Secondary Outcome Measures
Name Time Method